E. jbeekman@umcutrecht.nl
- Pulmonology Research 2
- Research
Biography
Biography
Dr. J.M. Beekman obtained a PhD in molecular immunology in 2004, and performed multiple post docs in molecular and cell biology within various immunological settings. In October 2010, he became principle investigator at the UMC Utrecht, and started a novel translational research line focusing on developing novel therapeutic strategies for cystic fibrosis, a genetic disease characterized by aberrant ion and fluid homeostasis at mucosal surfaces leading to chronic infection and inflammation and early death around the 3rd to 4th decade of life.
‘People with chronic diseases living healthy lives: I strive to create breakthrough solutions for clinical needs of people with chronic diseases by scientific research that focuses on the development of novel diagnostic or therapeutic approaches. This requires a multidisciplinary approach in which basic and clinical research is aligned, and integrated with needs of patients, the private sector and regulatory authorities. Currently, I am particularly proud of leading a team that developed a highly innovative diagnostic assay that enables individualized therapy for people with cystic fibrosis that lead to direct clinical impact for people within 4 years after the initial discovery.’
Side Activities
Professional activities
2021 Co-founder Fair Therapeutics
2020 Member selection committee for “3V-stimuleringsfonds” UU and UMCU
2019 Vice-president organizing committee European CF society conference 2022
2018 PhD Committee and opponent of Franz Shan Brunel, University of Aberdeen, UK
2017 PhD Committee and opponent of Karen Schelde, University of Aarhus, Denmark
2017 Consultant at CFF Theratyping workshop
2016 European CF society basic science working group – vice coordinator
2016 Grant reviewer Canadian Foundation for Innovation
2016 Grant reviewer Cystic Fibrosis Research, Inc. (CFRI)
2016 Grant reviewer German CF society
2016 Advisor for future funding of UK Cystic Fibrosis Trust (Research Sandpit Workshop, 8-9 Feb)
2015 Grant reviewer SRC grant application Cystic Fibrosis Trust (UK)
2015 Avicenna Roadmap Authoring Team – A strategy for in silico clinical trials
2013 –Editorial board member of Rare Diseases
2013 –Editorial board member of PlosOne
2013 –Annual candidate selection committee for Eureka Institute of Translational Medicine
2010 –Reviewer for various journals including Cell, Nature Medicine, Nature Communications, PlosOne, Journal of Immunological Methods, Journal of Leukocyte Biology, Molecular Immunology, Journal of Medical Genetics, Journal of Cystic Fibrosis
Memberships
2019-UWE, collaboration Utrecht-Wageningen-Eindhoven
2019-Membership transition-team for animal-free innovation Utrecht
2014 – European Respiratory Society
2010 –European Cystic Fibrosis Society
2011 –Eureka Institute for Translational Medicine
2000 –Dutch Society of Immunology (NVVI
Potential Conflicts of Interest
Dr Beekman has regular interactions with commercial parties including pharmaceutical companies, and performs academic associated research mostly in public-private partnerships or fee-for-service activities with such companies. Beekman was PI on grants with Galapagos, Proteostasis, and Eloxx Pharmaceuticals that led to major funding contributions from these companies to UMCU (>100K). Other companies provided in kind contributions. He is inventor of a patent (20210333266) that was licensed to Hubrecht Organoid Technology and he received personal royalties from 2017 onward (max annual income <3000 euros up to 2021) from the Royal Dutch Academy of Sciences and Arts. Dr Beekman has received personal support for preparation of meetings or consultancy (all below 2200 euro per event), or reimbursem*nt of traveling and lodging costs for participating in industry-sponsored educational meeting (all below €2200 per event). He co-founded FAIR therapeutics BV in 2021 and has a minority shareholders position.
Research Output (125)
Exploring intrinsic variability between cultured nasal and bronchial epithelia in cystic fibrosis
Rodenburg Lisa W, Metzemaekers Mieke, van der Windt Isabelle S, Smits Shannon M A, den Hertog-Oosterhoff Loes A, Kruisselbrink Evelien, Brunsveld Jesse E, Michel Sabine, de Winter-de Groot Karin M, van der Ent Cornelis K, Stadhouders Ralph, Beekman Jeffrey M, Amatngalim Gimano D 30 Oct 2023, In: Scientific Reports. 13
Lefferts Juliet W, Bierlaagh Marlou C, Kroes Suzanne, Nieuwenhuijze Natascha D A, Sonneveld van Kooten Heleen N, Niemöller Paul J, Verburg Tibo F, Janssens Hettie M, Muilwijk Danya, van Beuningen Sam F B, van der Ent Cornelis K, Beekman Jeffrey M Oct 2023, In: International Journal of Molecular Sciences. 24 14 p.
Rodenburg Lisa W, van der Windt Isabelle S, Dreyer Henriette H M, Smits Shannon M A, den Hertog-Oosterhoff Loes A, Aarts Ellen M, Beekman Jeffrey M, Amatngalim Gimano D 12 Jun 2023, In: STAR protocols. 4 , p. 1-28
Dreyer Henriette H.M., van Tuyll van Serooskerken Eleonora Sofie, Rodenburg Lisa W., Bittermann Arnold J.N., Arets Hubertus G.M., Reuling Ellen M.B.P., Verweij Johannes W., Haarman Eric G., van der Zee David C., Tytgat Stefaan H.A.J., van der Ent Cornelis K., Beekman Jeffrey M., Amatngalim Gimano D., Lindeboom Maud Y.A. 5 Jun 2023, In: Children (Basel, Switzerland). 10 , p. 1-9 9 p.
Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis
Birimberg-Schwartz Liron, Ip Wan, Bartlett Claire, Avolio Julie, Vonk Annelotte M., Gunawardena Tarini, Du Kai, Esmaeili Mohsen, Beekman Jeffrey M., Rommens Johanna, Strug Lisa, Bear Christine E., Moraes Theo J., Gonska Tanja Jun 2023, In: Life Science Alliance. 6
Lefferts J. W., Boersma V., Nieuwenhuijze N. D.A., Suen S. W.F., Hajo K., Collantes N. Sanchez, Vermeulen C., Groeneweg T., Hagemeijer M. C., de Jonge H. R., van der Ent C. K., Splinter E., Beekman J. M. May 2023, In: Journal of Cystic Fibrosis. 22 , p. 538-547 10 p.
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis
Leroy Catherine, Spelier Sacha, Essonghe Nadège Charlene, Poix Virginie, Kong Rebekah, Gizzi Patrick, Bourban Claire, Amand Séverine, Bailly Christine, Guilbert Romain, Hannebique David, Persoons Philippe, Arhant Gwenaëlle, Prévotat Anne, Reix Philippe, Hubert Dominique, Gérardin Michèle, Chamaillard Mathias, Prevarskaya Natalia, Rebuffat Sylvie, Shapovalov George, Beekman Jeffrey, Lejeune Fabrice 5 Apr 2023, In: Molecular Therapy. 31 , p. 970-985 16 p.
Readthrough compounds for nonsense mutations:bridging the translational gap
Spelier Sacha, van Doorn Eveline P.M., van der Ent Cornelis K., Beekman Jeffrey M., Koppens Martijn A.J. Apr 2023, In: Trends in molecular medicine. 29 , p. 297-314 18 p.
Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19
Rümke Lidewij W., Smit Wouter L., Bossink Ailko, Limonard Gijs J.M., Muilwijk Danya, Haas Lenneke E.M., Reusken Chantal, van der Wal Sanne, Thio Bing J., van Os Yvonne M.G., Gremmels Hendrik, Beekman Jeffrey M., Nijhuis Monique, Wensing Annemarie M.J., Heron Michiel, Thijsen Steven F.T. Apr 2023, In: Frontiers in Immunology. 14 9 p.
Spelier Sacha, de Poel Eyleen, Ithakisiou Georgia N., Suen Sylvia W.F., Hagemeijer Marne C., Muilwijk Danya, Vonk Annelotte M., Brunsveld Jesse E., Kruisselbrink Evelien, van der Ent Cornelis K., Beekman Jeffrey M. Jan 2023, In: ERJ Open Research. 9
All research output
Thank you for your review!
Has this information helped you?
